News Results
There are 371,855 News Results
Aug 7, 2024
Stem, Inc. (“Stem,” “we” or the “Company”) (NYSE: STEM), a global leader in artificial intelligence (AI)-driven clean energy solutions and services, announced today its financial results for the three and...
Aug 8, 2024
Clean Energy Fuels Corp. (NASDAQ: CLNE) (“Clean Energy” or the “Company”) today announced its operating results for the second quarter of 2024. Financial Highlights Revenue of $98.0 million in Q2...
Aug 9, 2024
New Fortress Energy Inc. (Nasdaq: NFE) (“NFE” or the “Company”) today reported its financial results for the second quarter of 2024. Summary Highlights Adjusted EBITDA(1) of $120 million in the...
Aug 20, 2024
RYBREVANT(® )plus LAZCLUZE(TM) is the first and only chemotherapy-free regimen showing superior progression-free survival versus osimertinib
Sep 8, 2024
New longer-term data from the MARIPOSA study confirm superior outcomes of chemotherapy-free RYBREVANT(®) plus LAZCLUZE(TM) regimen compared to osimertinib monotherapy as first-line therapy
Sep 10, 2024
Pre-medication regimen showed an infusion-related reaction rate of 22.5 percent with intravenous RYBREVANT(®), a three-fold reduction from 67.4 percent historically seen with standard IRR management
Sep 14, 2024
Post-progression outcomes showed significant and sustained improvement for RYBREVANT(®) plus standard of care versus chemotherapy alone
Sep 19, 2024
Approval based on compelling safety and efficacy from the Phase 3 MARIPOSA-2 study, marking the third new indication for RYBREVANT(®) this year, with four indications overall
